|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1996-12-26
|
|
pubmed:abstractText |
It was recently reported that when ifosfamide was added to cisplatin and vinblastine the response rate was increased but not the survival in patients with non-small-cell lung cancer (NSCLC). The purpose of this study was to investigate the possibility of increased responses and survival with use of the combination of cisplatin, ifosfamide, etoposide (VIP-16) in comparison to the combination of cisplatin, ifosfamide, vinblastine (VIP) in non-operable NSCLC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
517-20
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8839908-Adult,
pubmed-meshheading:8839908-Aged,
pubmed-meshheading:8839908-Antineoplastic Agents,
pubmed-meshheading:8839908-Antineoplastic Agents, Alkylating,
pubmed-meshheading:8839908-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:8839908-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8839908-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:8839908-Cisplatin,
pubmed-meshheading:8839908-Etoposide,
pubmed-meshheading:8839908-Female,
pubmed-meshheading:8839908-Humans,
pubmed-meshheading:8839908-Ifosfamide,
pubmed-meshheading:8839908-Lung Neoplasms,
pubmed-meshheading:8839908-Male,
pubmed-meshheading:8839908-Middle Aged,
pubmed-meshheading:8839908-Prognosis,
pubmed-meshheading:8839908-Prospective Studies,
pubmed-meshheading:8839908-Survival Rate,
pubmed-meshheading:8839908-Vinblastine
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group.
|
|
pubmed:affiliation |
Metaxa Cancer Hospital, Pireaus, Greece.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Clinical Trial, Phase III
|
